RARE
NASDAQ · Biotechnology
Ultragenyx Pharmaceutical In
$24.77
+0.08 (+0.32%)
Financial Highlights (FY 2026)
Revenue
708.75M
Net Income
-605,536,699
Gross Margin
83.8%
Profit Margin
-85.4%
Rev Growth
+22.8%
D/E Ratio
3.41
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 83.8% | 83.8% | 33.1% | 33.1% |
| Operating Margin | -79.5% | -71.5% | 6.2% | 7.5% |
| Profit Margin | -85.4% | -81.2% | 5.8% | 6.1% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 708.75M | 577.11M | 933.24M | 985.63M |
| Gross Profit | 593.93M | 483.62M | 308.73M | 326.06M |
| Operating Income | -563,386,027 | -412,871,447 | 58.15M | 73.93M |
| Net Income | -605,536,699 | -443,761,118 | 54.30M | 59.69M |
| Gross Margin | 83.8% | 83.8% | 33.1% | 33.1% |
| Operating Margin | -79.5% | -71.5% | 6.2% | 7.5% |
| Profit Margin | -85.4% | -81.2% | 5.8% | 6.1% |
| Rev Growth | +22.8% | +22.8% | -2.9% | -7.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 994.18M | 994.18M | 244.54M | 228.75M |
| Total Equity | 291.85M | 291.85M | 1.81B | 1.68B |
| D/E Ratio | 3.41 | 3.41 | 0.13 | 0.14 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -553,940,021 | -428,501,766 | 81.20M | 76.73M |
| Free Cash Flow | — | — | 84.57M | 73.09M |